Each vial contains: Aciclovir 250 mg.
Pharmacology: Pharmacokinetics: Aciclovir is widely distributed to body tissues and fluids including the CSF where concentrations achieved are about 50% of those achieved in plasma. Aciclovir is excreted largely unchanged in the urine by glomerular filtration and some active tubular secretion. In patients with normal renal function. the half life is about 2 to 3 hours.
Aciclovir is used for the treatment of initial and recurrent mucocutaneous Herpes Simplex Virus (HSV-1 and HSV-2) infections and the treatment of severe first episodes of genital herpes infections in immunocompetent individuals. It is also for the treatment of HSV encephalitis and neonatal HSV infections.
The maximum dosage of IV Aciclovir is 20 mg/kg every 8 hours. It is recommended that obese patients receive IV aciclovir dosages based on ideal body weight. Aciclovir solutions are administered by slow intravenous infusion (IV) infusion at constant rate over at least 1 hour. Prior to IV infusion, Aciclovir powder for injection must be reconstituted with 10 mL Sterile Water for Injection and then diluted with a compatible IV solution. Infusion concentrations of 7 mg/mL or lower are recommended.
This product is contraindicated in patients with history of hypersensitivity to aciclovir and other ingredients in the formulation.
Aciclovir should be used with caution in patients with underlying neurologic abnormalities and in patients with serious renal, or electrolyte abnormalities or substantial hypoxia. Caution must also be used in concurrent use of aciclovir with nephrotoxic drugs since the risk of aciclovir-induced renal impairment and/ or reversible CNS symptoms is increased. Systemic aciclovir should be used with caution and in reduced doses in patients with renal impairment. The elderly and patients with existing renal impairment should be closely monitored for neurological adverse effects. Adequate hydration should be maintained in patients given parenteral or high oral doses of aciclovir. Intravenous doses should be given by infusion over one hour to avoid precipitation of aciclovir in the kidney; rapid or bolus injection should be avoided. The risk of renal impairment is increased by use with other nephrotoxic drugs. Intravenous aciclovir should also be used with caution in patients with underlying neurological abnormalities, with significant hypoxia, or with serious hepatic or electrolyte abnormalities.
Intramuscular and subcutaneous injection must be avoided as well as rapid bolus intravenous injection.
Inflammation or phlebitis at the injection site and other adverse effects such as renal failure, fever and pain may occur.
For suspected adverse drug reaction, report to the FDA www.fda.gov.ph
Aciclovir should be used with caution in patients receiving intrathecal methotrexate or interferon. Also, probenecid blocks the renal clearance of aciclovir.
Store at temperatures not exceeding 30°C.
J05AB01 - aciclovir ; Belongs to the class of nucleosides and nucleotides excluding reverse transcriptase inhibitors. Used in the systemic treatment of viral infections.
Lyo powd for inj (vial) 250 mg x 10's.